<DOC>
	<DOCNO>NCT00068510</DOCNO>
	<brief_summary>RATIONALE : Vaccines make person 's white blood cell mixed tumor protein may make body build immune response kill tumor cell . PURPOSE : This phase I trial study side effect best dose vaccine therapy treat patient malignant glioma .</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients With Malignant Glioma</brief_title>
	<detailed_description>OBJECTIVES : - Determine dose-limiting toxicity maximum tolerate dose autologous tumor lysate-pulsed dendritic cell patient malignant glioma . - Determine survival , tumor progression , cellular immune response patient treat regimen . OUTLINE : This dose-escalation study . Patients undergo leukapheresis collection peripheral blood mononuclear cell ( PBMC ) . Autologous dendritic cell ( DC ) prepare autologous PBMC expose sargramostim ( GM-CSF ) interleukin-4 pulse autologous tumor lysate . Patients receive autologous tumor lysate-pulsed DC intradermally day 0 , 14 , 28 absence unacceptable toxicity . Cohorts 6-12 patient receive escalate dos autologous tumor lysate-pulsed DC maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Patients follow every 2 month 2 year . PROJECTED ACCRUAL : A total 3-18 patient accrue study within 9-18 month .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<criteria>Eligibility Criteria : Histologically confirm diagnosis one follow malignant glioma : Anaplastic astrocytoma Glioblastoma multiforme Anaplastic oligodendroglioma Malignant mixed oligoastrocytoma WHO grade III IV disease Newly diagnose disease Bidimensionally measurable disease contrastenhancing MRI Surgically accessible tumor resection indicate Previously treat plan undergo treatment conventional external beam radiotherapy Age 18 Performance status Karnofsky 60100 % Life expectancy least 8 week Hemoglobin least 10 g/dL Absolute granulocyte count least 1,500/mm^3 Platelet count least 100,000/mm^3 SGOT SGPT great 2 time normal Alkaline phosphatase great 2 time normal Bilirubin great 1.5 mg/dL Hepatitis B negative Hepatitis C negative BUN great 1.5 time normal Creatinine great 1.5 time normal HIV negative Syphilis serology negative Afebrile Negative pregnancy test Fertile patient must use effective contraception At least 2 week since prior chemotherapy ( 6 week nitrosoureas ) recover . At least 2 week since prior corticosteroid At least 2 week since prior radiotherapy recover More 72 hour since prior systemic antibiotic active infection immunodeficiency autoimmune disease may exacerbate immunotherapy , include follow : Rheumatoid arthritis Systemic lupus erythematosus Vasculitis Polymyositisdermatomyositis Scleroderma Multiple sclerosis Juvenileonset insulindependent diabetes allergy study agent pregnant nursing underlying condition would contraindicate study therapy concurrent severe unstable medical condition would preclude give informed consent psychiatric condition would preclude study participation give informed consent malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer , localize prostate cancer , carcinoma situ cervix concurrent chemotherapy 2 week administration study vaccine concurrent corticosteroid prior organ allograft antihistamine therapy within 5 day administration study vaccine concurrent investigational agent concurrent adjuvant therapy 2 week administration study vaccine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult brain tumor</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
	<keyword>adult anaplastic oligodendroglioma</keyword>
</DOC>